*NEW* Ataxia treatment pipeline launched! It is a visual look at drug development progress. LEARN MORE!

National Ataxia Foundation

Accelerate!

Day: January 15, 2021

NAF Supports FARA’s Call to Action

National Ataxia Foundation

Friedreich’s Ataxia Research Alliance (FARA) is encouraging Reata Pharmaceuticals to submit a New Drug Application (NDA) for Omaveloxolone, which recently completed a Phase III clinical trial as a treatment for Friedreich’s Ataxia (FA). FARA is also urging the Food and Drug Administration (FDA) to consider approving the NDA. FARA has prepared a letter that will Read More…


Translate »